@prefix dc1: <http://purl.org/dc/terms/> .
@prefix this: <http://purl.org/np/RA1gb3X1zHgvZrybBcUBn4yYrvnN0jFLrvOC8uth8XhAI> .
@prefix sub: <http://purl.org/np/RA1gb3X1zHgvZrybBcUBn4yYrvnN0jFLrvOC8uth8XhAI#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:Head {
  this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_11338> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_11338> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB01053> ;
    a rdf:Statement ;
    rdfs:label "penicillin g sodium for injection usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g therapy with penicillin g sodium for injection usp may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below however once these results become available appropriate therapy should be continued clinical indication infecting organism septicemia empyema pneumonia pericarditis endocarditis meningitis streptococcus pyogenes group a b hemolytic streptococcus other b hemolytic streptococci including groups c h g l and m streptococcus pneumoniae staphylococcus penicillinase producing strains anthrax bacillus anthracis actinomycosis cervico facial disease and thoracic and abdominal disease actinomyces israelil botulism adjunctive therapy to antitoxin gas gangrene and tetanus adjunctive therapy to human tetanus immune globulin clostridium species diphtheria adjunctive therapy to antitoxin and prevention of the carrier state corynebacterium diphtheriae erysipelothrix endocarditis erysipelothrix rhusiopthiae fusospirochetosis severe infections of the oropharynx vincent s lower respiratory tract and genital area fusobacterium species and spirochetes listeria infections including meningitis and endocarditis listeria monocytogenes pasteurella infections including bacteremia and meningitis pasteurella multocida haverhill fever streptobacillus moniliformis rat bite fever spirillum minus or streptobacillus moniliformis disseminated gonococcal infections neisseria gonorrhoeae penicillin susceptible syphilis congenital and neurosyphilis treponema pallidum meningococcal meningitis and or septicemia neisseria meningitidis gram negative bacillary infections bacteremias escherichia coli enterobacter aerogenes alcaligenes faecalis salmonella shigella proteus mirabilis is not the drug of choice in the treatment of gram negative bacillary infections to reduce the development of drug resistant bacteria and maintain the effectiveness of penicillin g sodium and other antibacterial drugs penicillin g sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB01053> bl:category bl:Drug .
}
sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" ;
    npx:hasSignature "W9OkUKj/VSTrw1mg+MEXlFiiDMWaFFym7T1sU4EQvttW0xHu4l9nuaPXjMBDV3IVuMznikLyi1X1Qb8Td5zx5+xWk5SJ2C08Monc9sYYzf4NIamCxT28DwcfN5O3oZOKQ6tYC9LhbrVMyAPiYbTxLpFwMDn3C1vGpquhUjnDTvQ=" ;
    npx:hasSignatureTarget this: .
  this: dc1:created "2021-06-13T16:28:36.010+02:00"^^xsd:dateTime ;
    dc1:creator orcid:0000-0002-1468-3557 ;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM> ;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM> ;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}